Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells - Wikidata - awgldk - TriplyDB

Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells

Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells

http://www.wikidata.org/entity/Q28829821

about

Integrins as Therapeutic Targets: Successes and Cancers.

P2860

Q41670949-1BD80ED5-6DAE-4415-993F-C3AF80A9CD82

P2860

Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells

http://www.wikidata.org/entity/Q28829821

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@ast

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@en

type

label

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@ast

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@en

prefLabel

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@ast

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@en

P1433

Q28829821-ED3BE1F4-C480-48A5-801C-B36A23FAF974

P1476

Q28829821-F0CA8509-F82E-4094-A4DC-BA32804655D8

P2093

Q28829821-0970EEB5-200D-4983-A799-C878031EB3DA

Q28829821-14A46954-E29A-42BE-8640-550636AA8E0A

Q28829821-2E913407-CD4E-46A1-A0A8-C3952FD4A6B0

Q28829821-3161D29E-8438-4B88-A2AD-60CC95D11D5C

Q28829821-3216CA89-EA16-4013-83C7-5977272A5E51

Q28829821-75F9EC92-766F-4932-BD60-5C6397CDD318

Q28829821-7CBDE8EB-713E-4724-90E2-BFEA77E030DA

Q28829821-9533E54F-3EE5-482D-88BA-B7F6C3C7FA74

Q28829821-AA87E02F-932A-44BF-9C55-8D76B2BC92A5

Q28829821-BCA210BC-6E17-4E77-BE52-7FF442E9AD75

P2860

Q28829821-1A0E44BE-F1E8-404E-94F2-0735D7F59714

Q28829821-3163A78F-0148-41A3-8BCB-610FF0112FD4

Q28829821-4C93907B-B150-4BDD-8068-716506AAE658

Q28829821-4F0F7A3C-77AB-4594-9642-91CEDA64C771

Q28829821-54B8CB2B-B8D5-49D6-B542-CA59098358D3

Q28829821-57C1684B-9A38-473B-A049-048D9F1A98D0

Q28829821-798982CC-8F30-4320-9039-8FBA6B60DF2E

Q28829821-80016787-A246-46F5-BB98-473AAEAB425A

Q28829821-8CDAAE2B-C25A-4253-AE78-93A8638E1AE1

Q28829821-90CD13BD-A141-43E1-8613-299DDD50C80F

P304

Q28829821-A33D0709-B7B5-4BF1-8778-064B1B3DAFF7

P31

Q28829821-914DED8A-913E-4860-A142-BB2F14E74133

P3181

Q28829821-44A3D563-4734-4B33-BC20-BB6319EBFC8C

P356

Q28829821-361FAA17-C27C-44D1-8195-69F4764AF62E

P407

Q28829821-BAC04FB5-E6FB-4B0A-97B2-340DFE17E15D

P433

Q28829821-C2FA5B43-E35F-4DD9-B3DA-4E08040B2296

P478

Q28829821-5795828D-E6CA-47F9-9355-A3DA32A11A4E

P577

Q28829821-69977EE2-BA3C-46F1-BE30-6C722B96B1F9

P698

Q28829821-E6E3C4A4-D9E5-4FA0-B378-7376111DA862

P932

Q28829821-32DD347A-736A-480B-BEA7-C8EA4D16C79F

P3181

P356

JBR.30.2016K0005

P1433

Journal of biomedical research

P1476

Novel monoclonal antibody agai ...... uman lung adenocarcinoma cells

@en

P2093

Da Bin Choi

http://www.w3.org/2001/XMLSchema#string

Ho-Chang Lee

http://www.w3.org/2001/XMLSchema#string

Hyung Geun Song

http://www.w3.org/2001/XMLSchema#string

Jeong Won Hong

http://www.w3.org/2001/XMLSchema#string

Kwon Pyo Hong

http://www.w3.org/2001/XMLSchema#string

Min-Young Kim

http://www.w3.org/2001/XMLSchema#string

Ok-Jun Lee

http://www.w3.org/2001/XMLSchema#string

Seung-Myoung Son

http://www.w3.org/2001/XMLSchema#string

Soseul Kim

http://www.w3.org/2001/XMLSchema#string

Woon-Dong Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2006

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity.

Global cancer statistics in the year 2000.

Differentiation requires continuous regulation.

IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis.

A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.

beta1 integrin as a molecular therapeutic target.

Volociximab in cancer.

P304

217-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2186497

http://www.w3.org/2001/XMLSchema#string

P356

10.7555/JBR.30.2016K0005

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27533932

http://www.w3.org/2001/XMLSchema#string

P932

4885170

http://www.w3.org/2001/XMLSchema#string